Daily Sepsis Research Analysis
Three impactful sepsis studies span from mechanistic biology to bedside care. A Cell Reports study identifies thiamine pyrophosphate depletion as a root cause of pyruvate dehydrogenase failure driving hyperlactatemia, with cofactor replacement protecting mice. Clinically, a meta-analysis shows prolonged meropenem infusion improves survival, and a large multicenter cohort validates a pragmatic 30-day mortality score for E. coli bacteremia.
Summary
Three impactful sepsis studies span from mechanistic biology to bedside care. A Cell Reports study identifies thiamine pyrophosphate depletion as a root cause of pyruvate dehydrogenase failure driving hyperlactatemia, with cofactor replacement protecting mice. Clinically, a meta-analysis shows prolonged meropenem infusion improves survival, and a large multicenter cohort validates a pragmatic 30-day mortality score for E. coli bacteremia.
Research Themes
- Mitochondrial metabolism and lactate pathobiology in sepsis
- Antibiotic dosing strategies: prolonged meropenem infusion
- Risk stratification in bloodstream infection (E. coli) with validated mortality score
Selected Articles
1. Unraveling mitochondrial pyruvate dysfunction to mitigate hyperlactatemia and lethality in sepsis.
In a CLP mouse model, sepsis nearly abolishes mitochondrial pyruvate-driven respiration due to pyruvate dehydrogenase complex failure caused by thiamine pyrophosphate depletion. TPP supplementation restores pyruvate oxidation, reduces hyperlactatemia, enables safe glucose administration, and improves survival.
Impact: This mechanistic study pinpoints a cofactor deficiency as a root cause of metabolic failure in sepsis and demonstrates a readily translatable rescue (TPP), opening a testable therapeutic avenue.
Clinical Implications: Consider early thiamine (TPP precursor) assessment/supplementation in septic patients with hyperlactatemia while definitive trials are conducted; findings rationalize ongoing interest in thiamine for lactate control.
Key Findings
- Sepsis abolishes mitochondrial pyruvate-driven respiration without defects in pyruvate uptake or carboxylation, implicating PDC dysfunction.
- PDC failure is driven by thiamine pyrophosphate shortage rather than enzyme inactivation.
- TPP supplementation restores pyruvate oxidation, reduces hyperlactatemia, allows safe glucose administration, and improves survival in mice.
Methodological Strengths
- Comprehensive interrogation of pyruvate metabolic routes with in vivo CLP model and mitochondrial assays.
- Causal rescue experiment demonstrating phenotype reversal with TPP supplementation.
Limitations
- Preclinical mouse study; human dosing, timing, and heterogeneity remain untested.
- Liver-focused mechanisms may not capture organ-specific variability in human sepsis.
Future Directions: Conduct early-phase clinical trials testing thiamine/TPP-guided resuscitation targeting hyperlactatemia; assess biomarker-driven selection and organ-specific metabolic phenotypes.
Sepsis, killing 11 million people yearly, is associated with increased production of lactate-a metabolite mechanistically linked to mortality-complicating glucose administration in sepsis. To understand the mechanism behind hyperlactatemia, we applied the cecal ligation and puncture (CLP) model and studied all pyruvate processing routes in liver mitochondria during acute sepsis. Our data suggest that mitochondrial pyruvate-driven respiration is nearly nonexistent in sepsis, not due to insufficient pyruvate uptake or carboxylation, but due to a dysfunctional pyruvate dehydrogenase complex (PDC). Septic mitochondria compensate via glutamate-mediated tricarboxylic acid (TCA) anaplerosis, simultaneously converting some pyruvate into alanine via enhanced mitochondrial glutamic pyruvate transaminase (GPT2) activity. PDC dysfunction is not caused by PDC inactivation per se but by a shortage of its cofactor, thiamine pyrophosphate (TPP). TPP supplementation restores pyruvate oxidation and protects mice from sepsis. TPP also allows safe glucose administration in mice, leading to a robust TPP-plus-glucose therapy.
2. Prolonged versus short-term infusion of meropenem for the treatment of sepsis: a systematic review and meta-analysis.
Across 18 studies (n=3703), prolonged meropenem infusion was associated with lower mortality (RR 0.85), higher clinical cure (RR 1.35), and higher microbiologic eradication (RR 1.13) compared with short infusions, with low heterogeneity.
Impact: Synthesizes the best available comparative evidence supporting pharmacokinetic/pharmacodynamic optimization of meropenem in sepsis with demonstrable survival benefit.
Clinical Implications: Clinicians should preferentially use prolonged (extended or continuous) meropenem infusion for sepsis when feasible, aligning dosing with PK/PD targets to improve outcomes.
Key Findings
- Prolonged infusion reduced mortality versus short-term infusion (RR 0.85, 95% CI 0.76–0.95) with low heterogeneity (I2=19%).
- Clinical cure rate was higher with prolonged infusion (RR 1.35, 95% CI 1.25–1.47).
- Microbiological eradication improved with prolonged infusion (RR 1.13, 95% CI 1.04–1.22).
Methodological Strengths
- PROSPERO-registered systematic review adhering to PRISMA.
- Inclusion of both RCTs and observational studies with low statistical heterogeneity.
Limitations
- Mixture of study designs and variable infusion protocols may introduce residual confounding.
- Long-term outcomes beyond short-term mortality were not established.
Future Directions: High-quality, adequately powered RCTs comparing extended vs continuous vs intermittent meropenem infusions with standardized PK/PD targets and long-term outcomes.
OBJECTIVES: The effectiveness of prolonged infusion of meropenem in treating sepsis remains debated. This meta-analysis aims to compare the clinical effectiveness and safety of prolonged infusion versus short-term infusion of meropenem in sepsis patients. METHODS: A systematic search was conducted in PubMed, Web of Science, ClinicalTrials.gov, and the Cochrane Library for randomized controlled trials (RCTs) and observational studies published from database inception up to February 2025. Studies meeting the inclusion and exclusion criteria were included. Data were extracted in prespecified forms, and fixed-effect or random-effects models were used based on I2 values. This meta-analysis is registered with the PROSPERO database and follows the Preferred Reporting Items for Systematic and Meta-Analyses reporting guidelines. RESULTS: A total of 1597 articles were identified and screened, leading to the inclusion of 18 studies (3703 patients) in the meta-analysis. Prolonged infusion of the meropenem was associated with a reduced risk of mortality compared to short-term infusion (risk ratio [RR] = 0.85, 95% confidence interval [CI] = 0.76-0.95). No significant heterogeneity was observed ( P = 0.24, I2 = 19%). Furthermore, prolonged infusion is associated with a higher rate of clinical cure (RR = 1.35, 95% CI = 1.25-1.47). Additionally, the group receiving prolonged infusions demonstrated a higher microbiological eradication rate (RR = 1.13, 95% CI = 1.04-1.22). CONCLUSIONS: Administering meropenem via prolonged infusion to sepsis patients is associated with short-term survival benefits, an increased likelihood of clinical cure, and greater microbiological eradication. Further high-quality RCTs are needed to determine the potential long-term survival benefits of prolonged meropenem infusion in sepsis patients.
3. Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort.
In a prospective multicenter cohort (26 hospitals), a 30-day mortality score for monomicrobial E. coli bacteremia was derived (n=1435) and validated (n=715), achieving AUROC 0.78 in both sets. Key predictors included age >55, dementia, liver disease, healthcare-associated acquisition, Pitt index >3, SOFA ≥2, with urinary tract source protective.
Impact: Provides a pragmatic, validated tool to stratify short-term mortality risk in a highly prevalent bloodstream infection, enabling targeted care escalation and stewardship.
Clinical Implications: Use the score at BSI diagnosis to identify high-risk patients for early ICU involvement, timely source control, and optimized empiric therapy; recognize urinary source as lower-risk.
Key Findings
- Derivation (n=1435) and validation (n=715) cohorts yielded AUROC 0.78 for 30-day mortality prediction.
- Independent risk factors: age >55, dementia, liver disease, healthcare-associated acquisition, Pitt index >3, SOFA ≥2; urinary source was protective (aOR 0.37).
- Internal validation demonstrated stable discrimination and calibration (Hosmer-Lemeshow and calibration plots).
Methodological Strengths
- Prospective, multicenter design with separate derivation and validation cohorts.
- Transparent multivariable modeling with discrimination and calibration assessment.
Limitations
- Internal validation only; external validation in other settings and populations is needed.
- Model limited to monomicrobial E. coli BSIs; generalizability to polymicrobial or other pathogens is unknown.
Future Directions: External validation across healthcare systems; impact analysis to test whether score-guided management improves outcomes and resource allocation.
INTRODUCTION: Escherichia coli is the most frequent cause of bacteraemia and has a major impact on morbidity and mortality. The aim of this study is to define and internally validate a predictive risk score of 30-day all-cause mortality. METHODS: A prospective, multicentre, cohort study conducted in 26 Spanish hospitals between October 2016 and March 2017 was performed. All monomicrobial E. coli bloodstream infections (BSIs) were included. The primary outcome was 30-day all-cause mortality. Cases were randomized to a derivation cohort (DC) and a validation cohort (VC). The predictive score was calculated from a multivariable model performed by logistic regression in the DC and subsequently applied to the VC. The predictive ability of the model was estimated by calculating the area under the ROC curve (AUROC) and the goodness of fit by Hosmer-Lemeshow test and calibration plot. RESULTS: Overall, 1435 cases were included in the DC and 715 in the VC. The final multivariable model for mortality in DC included (adjusted OR; 95% CI) age over 55 years (2.10; 1.01-4.36), dementia (2.08; 1.24-3.50), liver disease (1.81; 0.99-3.28), healthcare-associated acquisition (2.29; 1.52-3.44), Pitt index > 3 (3.59; 2.30-5.61), SOFA ≥ 2 (1.66; 1.04-2.64), and urinary tract source (0.37; 0.24-0.56). The predictive score showed an AUROC of 0.78 (95% CI 0.74-0.83) in the DC and 0.78 (95% CI 0.73-0.84) in the VC. CONCLUSION: We developed and internally validated a predictive scoring model to identify patients with E. coli bacteraemia at high and low risk of crude mortality on day 30 of BSI.